INVO Fertility (IVF)
Market Price (6/7/2026): $1.47 | Market Cap: $0.7 MilSector: Health Care | Industry: Life Sciences Tools & Services
INVO Fertility (IVF)
Market Price (6/7/2026): $1.47Market Cap: $0.7 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Reproductive Health & Fertility Solutions. Themes include Assisted Reproductive Technologies (ART), Fertility Diagnostics & Treatment Innovation, and Accessible Fertility Care. | Weak multi-year price returns2Y Excs Rtn is -140%, 3Y Excs Rtn is -177% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -104% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 174% Weak revenue growthRev Chg QQuarterly Revenue Change % is -6.1% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 21% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -103%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -103% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 1088% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3077% High stock price volatilityVol 12M is 447% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 26% Key risksIVF key risks include [1] severe financial strain, Show more. |
| Megatrend and thematic driversMegatrends include Reproductive Health & Fertility Solutions. Themes include Assisted Reproductive Technologies (ART), Fertility Diagnostics & Treatment Innovation, and Accessible Fertility Care. |
| Weak multi-year price returns2Y Excs Rtn is -140%, 3Y Excs Rtn is -177% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -104% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 174% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -6.1% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 21% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -103%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -103% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 1088% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3077% |
| High stock price volatilityVol 12M is 447% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 26% |
| Key risksIVF key risks include [1] severe financial strain, Show more. |
Qualitative Assessment
AI Analysis | Feedback
INVO Fertility (IVF) stock has lost about 65% since 2/28/2026 because of the following key factors:
1. Financial Statement Restatement and Accounting Errors: INVO Fertility announced on June 1, 2026, that its unaudited consolidated financial statements for the first, second, and third quarters of 2025 should no longer be relied upon due to identified accounting errors. This decision, following an internal review, necessitates a restatement of assets, liabilities, equity, other income (expense), and net income (loss) for those periods, significantly eroding investor confidence.
2. Nasdaq Non-Compliance and Delayed Filings: The company received a Nasdaq notification on April 29, 2026, for non-compliance with listing requirements due to its failure to file the Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This delay, attributed to a change in its independent registered public accounting firm and the need for additional time to review complex accounting matters, raised concerns about the company's operational and financial reporting stability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -66.5% change in IVF stock from 2/28/2026 to 6/6/2026 was primarily driven by a -81.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6062026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.75 | 1.59 | -66.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 7 | -1.5% |
| P/S Multiple | 0.1 | 0.1 | 88.2% |
| Shares Outstanding (Mil) | 0 | 0 | -81.9% |
| Cumulative Contribution | -66.5% |
Market Drivers
2/28/2026 to 6/6/2026| Return | Correlation | |
|---|---|---|
| IVF | -66.5% | |
| Market (SPY) | 7.8% | -15.7% |
| Sector (XLV) | -4.1% | 0.9% |
Fundamental Drivers
The -85.8% change in IVF stock from 11/30/2025 to 6/6/2026 was primarily driven by a -81.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6062026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.22 | 1.59 | -85.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 7 | -1.5% |
| P/S Multiple | 0.1 | 0.1 | -20.4% |
| Shares Outstanding (Mil) | 0 | 0 | -81.9% |
| Cumulative Contribution | -85.8% |
Market Drivers
11/30/2025 to 6/6/2026| Return | Correlation | |
|---|---|---|
| IVF | -85.8% | |
| Market (SPY) | 8.5% | -20.4% |
| Sector (XLV) | -2.1% | -3.0% |
Fundamental Drivers
The -99.2% change in IVF stock from 5/31/2025 to 6/6/2026 was primarily driven by a -97.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312025 | 6062026 | Change |
|---|---|---|---|
| Stock Price ($) | 202.80 | 1.59 | -99.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 7 | 3.8% |
| P/S Multiple | 0.4 | 0.1 | -68.8% |
| Shares Outstanding (Mil) | 0 | 0 | -97.6% |
| Cumulative Contribution | -99.2% |
Market Drivers
5/31/2025 to 6/6/2026| Return | Correlation | |
|---|---|---|
| IVF | -99.2% | |
| Market (SPY) | 26.6% | -14.9% |
| Sector (XLV) | 17.4% | -2.9% |
Fundamental Drivers
The -100.0% change in IVF stock from 5/31/2023 to 6/6/2026 was primarily driven by a -99.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312023 | 6062026 | Change |
|---|---|---|---|
| Stock Price ($) | 7332.48 | 1.59 | -100.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 7 | 578.9% |
| P/S Multiple | 3.5 | 0.1 | -96.9% |
| Shares Outstanding (Mil) | 0 | 0 | -99.9% |
| Cumulative Contribution | -100.0% |
Market Drivers
5/31/2023 to 6/6/2026| Return | Correlation | |
|---|---|---|
| IVF | -100.0% | |
| Market (SPY) | 83.4% | -2.9% |
| Sector (XLV) | 25.8% | 1.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IVF Return | 11% | -87% | -84% | -40% | -100% | -56% | -100% |
| Peers Return | 0% | -52% | 8% | -23% | 3% | 1% | -58% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| IVF Win Rate | 50% | 25% | 42% | 33% | 8% | 17% | |
| Peers Win Rate | 51% | 35% | 48% | 42% | 48% | 38% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 67% | |
Max Drawdowns [4] | |||||||
| IVF Max Drawdown | -69% | -90% | -97% | -64% | -100% | -95% | |
| Peers Max Drawdown | -31% | -61% | -50% | -54% | -47% | -39% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: COO, PGNY, FEMY, CYRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/5/2026 (YTD)
How Low Can It Go
| Event | IVF | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -41.3% | -33.7% |
| % Gain to Breakeven | 70.5% | 50.9% |
| Time to Breakeven | 323 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -12.5% | -19.2% |
| % Gain to Breakeven | 14.2% | 23.8% |
| Time to Breakeven | 26 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -31.4% | -3.7% |
| % Gain to Breakeven | 45.8% | 3.9% |
| Time to Breakeven | 15 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -10.9% | -12.2% |
| % Gain to Breakeven | 12.2% | 13.9% |
| Time to Breakeven | 5 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -29.2% | -6.8% |
| % Gain to Breakeven | 41.2% | 7.3% |
| Time to Breakeven | 9 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -44.0% | -0.2% |
| % Gain to Breakeven | 78.6% | 0.2% |
| Time to Breakeven | 12 days | 1 days |
In The Past
INVO Fertility's stock fell -6.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 6.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | IVF | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -41.3% | -33.7% |
| % Gain to Breakeven | 70.5% | 50.9% |
| Time to Breakeven | 323 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -31.4% | -3.7% |
| % Gain to Breakeven | 45.8% | 3.9% |
| Time to Breakeven | 15 days | 6 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -29.2% | -6.8% |
| % Gain to Breakeven | 41.2% | 7.3% |
| Time to Breakeven | 9 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -44.0% | -0.2% |
| % Gain to Breakeven | 78.6% | 0.2% |
| Time to Breakeven | 12 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -57.1% | -17.9% |
| % Gain to Breakeven | 133.3% | 21.8% |
| Time to Breakeven | 102 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -50.0% | -53.4% |
| % Gain to Breakeven | 100.0% | 114.4% |
| Time to Breakeven | 1 days | 1085 days |
In The Past
INVO Fertility's stock fell -6.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 6.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About INVO Fertility (IVF)
AI Analysis | Feedback
nullAI Analysis | Feedback
- NY-303: A GPC3 and NKp46 targeting bispecific antibody developed for the treatment of hepatocellular carcinoma (HCC).
- NY-338: A CD38 and NKp46 targeting bispecific antibody designed for the treatment of multiple myeloma and autoimmune diseases.
- INVOcell®: An FDA-approved medical device used in fertility treatments, offering an alternative to traditional In Vitro Fertilization (IVF).
AI Analysis | Feedback
Major Customers for the INVOcell® Fertility Device (an asset of NAYA Biosciences)
Based on the provided background, the company in question is NAYA Biosciences (NASDAQ: NAYA), which now owns and operates the INVOcell® fertility device. While INVO Fertility (formerly INVO Bioscience) previously traded under the symbol IVF and was known for INVOcell®, it has since been acquired by NAYA Biosciences. Therefore, the customers identified below pertain to the INVOcell® fertility device, which is an asset within NAYA Biosciences's portfolio.
As INVOcell® is an FDA-approved medical device used in fertility treatments, its primary customers are not individual patients but rather healthcare providers and institutions that offer these specialized services. The major categories of "other companies" that purchase and utilize the INVOcell® device are:
- Fertility Clinics and Reproductive Endocrinology and Infertility (REI) Centers: These specialized private practices or larger clinic networks are the primary direct users of fertility devices like INVOcell®. They integrate these devices into their service offerings as part of comprehensive fertility treatment options for patients.
- Hospital Systems with Fertility Departments: Many larger hospital networks and healthcare systems include dedicated departments or affiliated centers for reproductive medicine. These institutional customers may acquire and integrate INVOcell® into their range of fertility services.
- Academic Medical Centers and Research Institutions: Universities and teaching hospitals often have reproductive health programs that not only provide clinical care but also engage in research. They may acquire INVOcell® for both patient treatment and for study purposes related to assisted reproductive technologies.
These customer entities are typically private organizations and, as such, do not have public stock symbols.
AI Analysis | Feedback
nullAI Analysis | Feedback
Steven M. Schum, Chief Executive Officer
Steven M. Schum, who holds a PharmD and MBA, was the CEO of INVO Bioscience before its merger with NAYA Biosciences. He became the Chief Executive Officer of the combined NAYA Biosciences. He has expressed confidence in the expanded portfolio business model, which integrates the profitable revenues from the fertility business with innovative therapeutics.
Andrea Goren, Chief Financial Officer
Andrea Goren, who holds an MSc, served as the CFO of INVO Bioscience prior to the merger and now holds the position of Chief Financial Officer for the combined NAYA Biosciences.
Daniel Teper, President
Daniel Teper, who holds a PharmD and MBA, is the Founder and President of NAYA Biosciences, and also serves as the Chief Executive Officer of its NAYA Therapeutics subsidiary. He brings over 30 years of strategic leadership experience as a biopharma entrepreneur, corporate executive, and management consultant. Dr. Teper previously held the roles of Chairman & CEO of Cytovia Therapeutics and CEO of Immune Pharmaceuticals, which he successfully led to a NASDAQ-listing. His experience includes senior management positions at Novartis, GlaxoSmithKline, and Sanofi, and he was a Managing Partner at Bionest Partners (now Accenture) and a Partner at ISO Healthcare (now Deloitte). He is also the Executive Chairman of Imaginostics and a member of the supervisory board of Crossject.
Mark Rothera, Strategic Advisor to the CEO
Mark Rothera holds an MBA and serves as a Strategic Advisor to the Chief Executive Officer at NAYA Biosciences.
Anna Baran-Djokovic, SVP, Investor Relations
Anna Baran-Djokovic holds an MSc and is the SVP, Investor Relations for NAYA Biosciences.
AI Analysis | Feedback
INVO Fertility, trading under the symbol IVF, faces several key risks as it focuses exclusively on the fertility marketplace, including the operation of fertility clinics and the distribution of its FDA-cleared INVOcell device. Here are the key risks to the business: 1.Market Adoption and Competition
INVO Fertility's primary commercial offering, the INVOcell device, competes with established traditional in vitro fertilization (IVF) methods. While INVOcell is marketed as a more natural and cost-effective alternative with comparable success rates, challenges exist in achieving widespread market adoption, physician acceptance, and patient preference. Some sources suggest that INVOcell may yield fewer embryos and that the inability to monitor embryo development during intravaginal culture could be a disadvantage compared to advanced IVF techniques. Furthermore, the company's strategy to acquire and operate fertility clinics introduces risks related to integrating new operations and maintaining profitability in a competitive healthcare services market. The broader IVF devices market, while growing, is also characterized by high treatment costs and regulatory complexities. 2.Regulatory and Legal Risks in Fertility Services
The company operates in a highly regulated and politically sensitive sector. Specifically, shifts in federal abortion laws have already caused disruptions in INVO Fertility's existing INVO Centers in Alabama and Georgia, and these evolving state-specific regulations could continue to impact operations. The fertility industry as a whole can be subject to stringent governmental regulations and ongoing ethical debates, which could pose compliance challenges and influence market dynamics. 3.Capital Requirements and Funding Risk for Expansion
INVO Fertility's strategic growth plan involves acquiring and establishing new fertility clinics across the United States. This expansion is a capital-intensive endeavor, requiring significant funding. The company's ability to secure additional capital on favorable terms will be crucial for executing its growth strategy. Past financial performance has indicated stress, including a significant stock price decline post-merger and delays in reporting earnings, underscoring the potential challenges in financing future growth initiatives.AI Analysis | Feedback
nullAI Analysis | Feedback
INVO Fertility (NASDAQ: IVF) offers INVOcell®, an FDA-approved fertility device that facilitates fertilization and early embryo development within the woman's body. The company also operates fertility clinics. The addressable markets for INVO Fertility's main products and services are primarily within the broader fertility treatment and IVF device markets.
The global market for IVF devices, which includes specialized medical equipment and consumables for assisted reproductive technology, was valued at approximately USD 2.85 billion in 2024 and is projected to reach about USD 13.51 billion by 2034, growing at a compound annual growth rate (CAGR) of 16.84% from 2025 to 2034. For the United States, the IVF devices and consumables market was approximately USD 698.25 million in 2024, with projections indicating growth to around USD 3.38 billion by 2034, at a CAGR of 17.09% from 2025 to 2034.
Looking at the broader fertility treatment market, the global in-vitro fertilization (IVF) market size was calculated at USD 32.11 billion in 2025 and is predicted to increase to approximately USD 68.57 billion by 2034, expanding at a CAGR of 8.80% from 2025 to 2034. In the United States, the fertility market was valued at USD 8.37 billion in 2024 and is predicted to increase to approximately USD 19.72 billion by 2034, expanding at a CAGR of 9.10% from 2025 to 2034.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for INVO Fertility (IVF) over the next 2-3 years:- Acquisition of New Fertility Clinics: INVO Fertility's primary commercial strategy involves acquiring and operating fertility clinics. The company has a robust acquisition pipeline and anticipates completing further acquisitions, such as the recently closed acquisition of Family Beginnings in Indiana in February 2026. These acquisitions are expected to diversify revenue streams and enhance earnings potential.
- Organic Growth within Existing Clinics: The company is focused on increasing patient volumes, optimizing treatment pathways, and enhancing the patient experience within its current network of clinics. Initiatives such as targeted marketing, improved patient access, physician recruitment, and expanded service offerings (including advanced incubation technology) are expected to drive incremental growth.
- Expansion and Adoption of the INVOcell Device: INVO Fertility markets the INVOcell® medical device, which enables the intravaginal culture (IVC) procedure. The company is expanding clinical and embryology training support and has implemented improved pricing for INVOcell to make it more accessible and attractive to both patients and clinic operators, contributing to significant year-over-year device revenue growth.
- Increasing Market Awareness and Demand for ART/IVC Procedures: The global fertility services market is projected to grow due to rising infertility rates and increasing acceptance of assisted reproductive technologies (ART). INVO Fertility aims to boost market awareness for its INVOcell technology through educational campaigns, positioning itself to benefit from the broader demand for fertility care.
AI Analysis | Feedback
Capital Allocation Decisions for INVO Fertility (IVF)
Share Issuance
- In January 2025, NAYA Biosciences (the entity which INVO Fertility became) priced a public offering of 13,615,171 units at $0.70 per unit, raising approximately $9.5 million in gross proceeds. Each unit included one share of common stock (or pre-funded warrant) and one warrant to purchase one share of common stock.
- In August 2023, INVO Bioscience closed a public offering of 1,580,000 units at $2.85 per unit, generating approximately $4.5 million in gross proceeds. Each unit consisted of one share of common stock and two warrants.
- In March 2023, INVO Bioscience issued 1,380,000 shares of common stock, pre-funded warrants for 2,300,000 shares, and common stock purchase warrants for 5,520,000 shares, resulting in approximately $3 million in gross proceeds.
Inbound Investments
- INVO Bioscience raised $12.3 million through private equity in 2023, with $7.5 million occurring in that year.
- In October 2024, INVO Bioscience completed a merger with NAYA Biosciences in an all-stock transaction. NAYA Biosciences' shareholders received approximately 18,150,000 shares of INVO, leading NAYA equity holders to own roughly 88% of the combined company.
Outbound Investments
- INVO Bioscience acquired the Wisconsin Fertility Institute for $10 million in 2023, with an initial down payment of $2.15 million and subsequent installment payments planned over three years.
- In April 2025, NAYA Biosciences (which was the combined entity) announced its intention to divest its majority stake in NAYA Therapeutics to focus on its core fertility business.
Capital Expenditures
- In the most recent quarter (Q4 2025), INVO Fertility's capital expenditures totaled -$0.008 million USD, indicating a net reduction in capital assets.
- In 2023, the company was nearing completion of the buildout of its new Tampa, Florida clinic, the Tampa Fertility Institute.
- The company plans to continue its growth strategy by acquiring additional IVF clinics, with the acquisition of a fourth clinic in Indianapolis nearing completion as of February 2026.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.70 |
| Mkt Cap | 0.8 |
| Rev LTM | 183 |
| Op Inc LTM | -7 |
| FCF LTM | -7 |
| FCF 3Y Avg | -5 |
| CFO LTM | -1 |
| CFO 3Y Avg | -5 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.6% |
| Rev Chg 3Y Avg | 14.3% |
| Rev Chg Q | 6.2% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Inc Chg LTM | 17.3% |
| Op Inc Chg 3Y Avg | 9.9% |
| Op Mgn LTM | -21.4% |
| Op Mgn 3Y Avg | -30.6% |
| QoQ Delta Op Mgn LTM | 0.8% |
| CFO/Rev LTM | -0.3% |
| CFO/Rev 3Y Avg | -5.3% |
| FCF/Rev LTM | -14.3% |
| FCF/Rev 3Y Avg | -23.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 3.2 |
| P/Op Inc | -0.1 |
| P/EBIT | -0.0 |
| P/E | 10.3 |
| P/CFO | -0.1 |
| Total Yield | 3.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -8.1% |
| D/E | 0.2 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 10.2% |
| 3M Rtn | -12.0% |
| 6M Rtn | -17.3% |
| 12M Rtn | -6.9% |
| 3Y Rtn | -36.0% |
| 1M Excs Rtn | 9.9% |
| 3M Excs Rtn | -21.6% |
| 6M Excs Rtn | -19.2% |
| 12M Excs Rtn | -23.8% |
| 3Y Excs Rtn | -107.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Fertility Clinic Services | 3 | ||||
| INVOcell Device | 0 | ||||
| Intersegment revenues | 0 | ||||
| Therapeutics | 0 | ||||
| Clinic revenue | 1 | 0 | |||
| Product revenue | 0 | 1 | 0 | 1 | |
| License revenue | 4 | 1 | 1 | ||
| Total | 3 | 1 | 4 | 1 | 1 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| INVOcell Device | 0 | ||||
| Fertility Clinic Services | 0 | ||||
| Elimination of intersegment revenue | 0 | ||||
| Therapeutics | 0 | ||||
| Other corporate expenses | -7 | ||||
| Total | -7 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Fertility Clinic Services | 11 | ||||
| INVOcell Device | 0 | ||||
| Therapeutics | 0 | ||||
| Total | 11 |
Price Behavior
| Market Price | $1.59 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/11/2008 | |
| Distance from 52W High | -99.1% | |
| 50 Days | 200 Days | |
| DMA Price | $1.95 | $12.95 |
| DMA Trend | down | down |
| Distance from DMA | -18.3% | -87.7% |
| 3M | 1YR | |
| Volatility | 753.6% | 448.3% |
| Downside Capture | 336.83 | 384.09 |
| Upside Capture | -140.47 | -277.41 |
| Correlation (SPY) | -17.9% | -15.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.78 | 1.58 | -8.97 | -10.07 | -5.79 | -0.67 |
| Up Beta | 1.46 | 2.58 | 5.01 | 3.18 | 0.20 | 0.12 |
| Down Beta | -4.05 | -0.12 | -41.75 | -40.97 | -20.62 | -1.60 |
| Up Capture | 181% | -67% | -43% | -95% | -67% | -7% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 13 | 19 | 39 | 87 | 279 |
| Down Capture | 472% | 425% | 346% | 240% | 207% | 113% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 11 | 26 | 42 | 83 | 158 | 447 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IVF | |
|---|---|---|---|---|
| IVF | -99.2% | 446.5% | 0.04 | - |
| Sector ETF (XLV) | 16.9% | 15.0% | 0.83 | -2.9% |
| Equity (SPY) | 25.3% | 12.1% | 1.57 | -14.9% |
| Gold (GLD) | 27.6% | 26.9% | 0.88 | 3.8% |
| Commodities (DBC) | 36.9% | 19.0% | 1.52 | 7.8% |
| Real Estate (VNQ) | 12.5% | 13.3% | 0.63 | -1.5% |
| Bitcoin (BTCUSD) | -42.0% | 42.5% | -1.16 | -8.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IVF | |
|---|---|---|---|---|
| IVF | -89.5% | 273.5% | -0.08 | - |
| Sector ETF (XLV) | 6.1% | 14.7% | 0.23 | 3.0% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 1.4% |
| Gold (GLD) | 17.3% | 18.1% | 0.78 | 2.7% |
| Commodities (DBC) | 9.5% | 19.4% | 0.38 | 3.9% |
| Real Estate (VNQ) | 3.2% | 18.8% | 0.07 | 2.7% |
| Bitcoin (BTCUSD) | 11.3% | 54.6% | 0.40 | 3.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IVF | |
|---|---|---|---|---|
| IVF | -69.1% | 218.3% | 0.09 | - |
| Sector ETF (XLV) | 9.9% | 16.6% | 0.48 | 2.1% |
| Equity (SPY) | 15.3% | 17.9% | 0.73 | 2.3% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 2.6% |
| Commodities (DBC) | 7.1% | 18.0% | 0.32 | 2.7% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 1.0% |
| Bitcoin (BTCUSD) | 63.3% | 66.9% | 1.03 | 2.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/5/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 6/2/2026 | 3.4% | ||
| 11/17/2025 | -5.1% | -32.2% | -72.4% |
| 8/15/2025 | -10.2% | -28.7% | -39.5% |
| 5/21/2025 | -10.3% | -20.6% | -44.0% |
| 8/14/2024 | -3.8% | -6.9% | -20.3% |
| 5/15/2024 | -6.5% | -14.6% | -3.7% |
| 11/13/2023 | 34.2% | 6.8% | -25.5% |
| 8/14/2023 | -15.7% | -11.2% | -36.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 2 | 3 |
| # Negative | 13 | 15 | 14 |
| Median Positive | 5.1% | 5.3% | 13.3% |
| Median Negative | -6.6% | -11.2% | -40.0% |
| Max Positive | 34.2% | 6.8% | 23.0% |
| Max Negative | -29.4% | -34.6% | -72.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 06/02/2026 | 10-K |
| 09/30/2025 | 11/17/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/20/2025 | 10-Q |
| 12/31/2024 | 04/30/2025 | 10-K |
| 09/30/2024 | 11/19/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/16/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 04/17/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/16/2022 | 10-Q |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Szot, Matthew K | Direct | Sell | 12052025 | 1.52 | 4 | 6 | 5 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.